APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Vaccine

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

Selected research

Market Structure

Global Varicella Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025186 pages

Choose your research edition.

Industry ResearchVaricella Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Vaccine Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Varicella Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Vaccine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.

Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.

Read the full market overview

In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.

This report provides an overview of the global Varicella Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Vaccine Segment by Company

Merck

GSK

Shanghai Institute

BCHT

Changsheng

Keygen

Green Cross

Biken

Varicella Vaccine Segment by Type

Injection

Freeze-Dried Powder

Varicella Vaccine Segment by Application

Kids Injection

Adults Injection

Varicella Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Varicella Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Varicella Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Varicella Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Varicella Vaccine Industry Trends Table 2. Varicella Vaccine Industry Drivers Table 3. Varicella Vaccine Industry Opportunities and Challenges Table 4. Varicella Vaccine Industry Restraints Table 5. Global Varicella Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Varicella Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Varicella Vaccine Sales by Manufacturers (M Doses) & (2021-2026) Table 8. Global Varicella Vaccine Sales Market Share by Manufacturers Table 9. Global Varicella Vaccine Average Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 10. Global Varicella Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Varicella Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Varicella Vaccine Manufacturers, Product Type & Application Table 13. Global Varicella Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injection Table 17. Major Manufacturers of Freeze-Dried Powder Table 18. Global Varicella Vaccine Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 19. Global Varicella Vaccine Sales by Type (2021-2026) & (M Doses) Table 20. Global Varicella Vaccine Sales by Type (2027-2032) & (M Doses) Table 21. Global Varicella Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Varicella Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Varicella Vaccine Revenue by Type 2021 VS 2025 VS 2032 (M Doses) Table 24. Global Varicella Vaccine Revenue by Type (2021-2026) & (M Doses) Table 25. Global Varicella Vaccine Revenue by Type (2027-2032) & (M Doses) Table 26. Global Varicella Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Varicella Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Kids Injection Table 29. Major Manufacturers of Adults Injection Table 30. Global Varicella Vaccine Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 31. Global Varicella Vaccine Sales by Application (2021-2026) & (M Doses) Table 32. Global Varicella Vaccine Sales by Application (2027-2032) & (M Doses) Table 33. Global Varicella Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Varicella Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Varicella Vaccine Revenue by Application 2021 VS 2025 VS 2032 (M Doses) Table 36. Global Varicella Vaccine Revenue by Application (2021-2026) & (M Doses) Table 37. Global Varicella Vaccine Revenue by Application (2027-2032) & (M Doses) Table 38. Global Varicella Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Varicella Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Varicella Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 41. Global Varicella Vaccine Sales by Region (2021-2026) & (M Doses) Table 42. Global Varicella Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Varicella Vaccine Sales Forecasted by Region (2027-2032) & (M Doses) Table 44. Global Varicella Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 46. North America Varicella Vaccine Sales by Country (2021-2026) & (M Doses) Table 47. North America Varicella Vaccine Sales by Country (2027-2032) & (M Doses) Table 48. Europe Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 49. Europe Varicella Vaccine Sales by Country (2021-2026) & (M Doses) Table 50. Europe Varicella Vaccine Sales by Country (2027-2032) & (M Doses) Table 51. Asia Pacific Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 52. Asia Pacific Varicella Vaccine Sales by Country (2021-2026) & (M Doses) Table 53. Asia Pacific Varicella Vaccine Sales by Country (2027-2032) & (M Doses) Table 54. South America, Middle East and Africa Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 55. South America, Middle East and Africa Varicella Vaccine Sales by Country (2021-2026) & (M Doses) Table 56. South America, Middle East and Africa Varicella Vaccine Sales by Country (2027-2032) & (M Doses) Table 57. Global Varicella Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Varicella Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Varicella Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Varicella Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Varicella Vaccine Revenue Market Share by Region (2027-2032) Table 62. Merck Company Information Table 63. Merck Business Overview Table 64. Merck Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Merck Varicella Vaccine Product Portfolio Table 66. Merck Recent Development Table 67. GSK Company Information Table 68. GSK Business Overview Table 69. GSK Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. GSK Varicella Vaccine Product Portfolio Table 71. GSK Recent Development Table 72. Shanghai Institute Company Information Table 73. Shanghai Institute Business Overview Table 74. Shanghai Institute Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Shanghai Institute Varicella Vaccine Product Portfolio Table 76. Shanghai Institute Recent Development Table 77. BCHT Company Information Table 78. BCHT Business Overview Table 79. BCHT Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. BCHT Varicella Vaccine Product Portfolio Table 81. BCHT Recent Development Table 82. Changsheng Company Information Table 83. Changsheng Business Overview Table 84. Changsheng Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Changsheng Varicella Vaccine Product Portfolio Table 86. Changsheng Recent Development Table 87. Keygen Company Information Table 88. Keygen Business Overview Table 89. Keygen Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Keygen Varicella Vaccine Product Portfolio Table 91. Keygen Recent Development Table 92. Green Cross Company Information Table 93. Green Cross Business Overview Table 94. Green Cross Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Green Cross Varicella Vaccine Product Portfolio Table 96. Green Cross Recent Development Table 97. Biken Company Information Table 98. Biken Business Overview Table 99. Biken Varicella Vaccine Sales (M Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Biken Varicella Vaccine Product Portfolio Table 101. Biken Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Varicella Vaccine Distributors List Table 105. Varicella Vaccine Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Varicella Vaccine Product Image Figure 2. Global Varicella Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Varicella Vaccine Sales (2021-2032) & (M Doses) Figure 5. Global Varicella Vaccine Average Price (USD/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Varicella Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injection Image Figure 9. Freeze-Dried Powder Image Figure 10. Global Varicella Vaccine Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 11. Global Varicella Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Varicella Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Varicella Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 14. Global Varicella Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Varicella Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Kids Injection Image Figure 17. Adults Injection Image Figure 18. Global Varicella Vaccine Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 19. Global Varicella Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Varicella Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Varicella Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 22. Global Varicella Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Varicella Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 25. North America Varicella Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 27. Canada Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 28. Mexico Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 29. Europe Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 30. Europe Varicella Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 32. France Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 33. U.K. Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 34. Italy Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 35. Netherlands Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 36. Asia Pacific Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 37. Asia Pacific Varicella Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 39. Japan Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 40. South Korea Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 41. Southeast Asia Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 42. India Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 43. Australia Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 44. South America, Middle East and Africa Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 45. South America, Middle East and Africa Varicella Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 47. South Africa Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 48. Saudi Arabia Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 49. Turkey Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 50. Argentina Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 51. UAE Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 52. Egypt Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 53. Chile Varicella Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 54. Global Varicella Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Varicella Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Varicella Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Varicella Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Varicella Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Varicella Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Varicella Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Varicella Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Freeze-Dried Powder
Applications
  • Kids Injection
  • Adults Injection
Companies covered
  • Merck
  • GSK
  • Shanghai Institute
  • BCHT
  • Changsheng
  • Keygen
  • Green Cross
  • Biken

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Varicella Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Varicella Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Varicella Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Varicella Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Varicella Vaccine Market Dynamics
  1. 2.1 Varicella Vaccine Industry Trends
  2. 2.2 Varicella Vaccine Industry Drivers
  3. 2.3 Varicella Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Vaccine Industry Restraints
3 Varicella Vaccine Market by Manufacturers
  1. 3.1 Global Varicella Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Varicella Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Varicella Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Varicella Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Varicella Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Varicella Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Varicella Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Varicella Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Varicella Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Varicella Vaccine Tier 1, Tier 2, and Tier 3
4 Varicella Vaccine Market by Type
  1. 4.1 Varicella Vaccine Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Freeze-Dried Powder
  4. 4.2 Global Varicella Vaccine Sales by Type
  5. 4.2.1 Global Varicella Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Varicella Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Varicella Vaccine Revenue by Type
  9. 4.3.1 Global Varicella Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Varicella Vaccine Revenue Market Share by Type (2021-2032)
5 Varicella Vaccine Market by Application
  1. 5.1 Varicella Vaccine Application Introduction
  2. 5.1.1 Kids Injection
  3. 5.1.2 Adults Injection
  4. 5.2 Global Varicella Vaccine Sales by Application
  5. 5.2.1 Global Varicella Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Varicella Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Varicella Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Varicella Vaccine Revenue by Application
  9. 5.3.1 Global Varicella Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Varicella Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Varicella Vaccine Revenue Market Share by Application (2021-2032)
6 Global Varicella Vaccine Sales by Region
  1. 6.1 Global Varicella Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Varicella Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Varicella Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Varicella Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Varicella Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Varicella Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Varicella Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Varicella Vaccine Revenue by Region
  1. 7.1 Global Varicella Vaccine Revenue by Region
  2. 7.1.1 Global Varicella Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Varicella Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Varicella Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Varicella Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Varicella Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Varicella Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Varicella Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Varicella Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Varicella Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Varicella Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GSK Varicella Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Shanghai Institute
  14. 8.3.1 Shanghai Institute Company Information
  15. 8.3.2 Shanghai Institute Business Overview
  16. 8.3.3 Shanghai Institute Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Institute Varicella Vaccine Product Portfolio
  18. 8.3.5 Shanghai Institute Recent Developments
  19. 8.4 BCHT
  20. 8.4.1 BCHT Company Information
  21. 8.4.2 BCHT Business Overview
  22. 8.4.3 BCHT Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BCHT Varicella Vaccine Product Portfolio
  24. 8.4.5 BCHT Recent Developments
  25. 8.5 Changsheng
  26. 8.5.1 Changsheng Company Information
  27. 8.5.2 Changsheng Business Overview
  28. 8.5.3 Changsheng Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Changsheng Varicella Vaccine Product Portfolio
  30. 8.5.5 Changsheng Recent Developments
  31. 8.6 Keygen
  32. 8.6.1 Keygen Company Information
  33. 8.6.2 Keygen Business Overview
  34. 8.6.3 Keygen Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Keygen Varicella Vaccine Product Portfolio
  36. 8.6.5 Keygen Recent Developments
  37. 8.7 Green Cross
  38. 8.7.1 Green Cross Company Information
  39. 8.7.2 Green Cross Business Overview
  40. 8.7.3 Green Cross Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Green Cross Varicella Vaccine Product Portfolio
  42. 8.7.5 Green Cross Recent Developments
  43. 8.8 Biken
  44. 8.8.1 Biken Company Information
  45. 8.8.2 Biken Business Overview
  46. 8.8.3 Biken Varicella Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biken Varicella Vaccine Product Portfolio
  48. 8.8.5 Biken Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Vaccine Production Mode & Process
  6. 9.2 Varicella Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Vaccine Distributors
  9. 9.2.3 Varicella Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst